Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AFFYMETRIX (AFFX) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1557)	5/21/2002 12:47:41 PM
From: tuck	Read Replies (1) \| Respond to of 1728

>>TIGR, Affy Finish Newly Annotated Arabidopsis Array By a GenomeWeb staff reporter NEW YORK, May 17 - The Institute for Genomic Research and Affymetrix have completed a newly re-annotated Arabidopsis thaliana array, TIGR said on Wednesday. The updated array, which was developed under a cooperative agreement with the National Science Foundations, is based on data from the international Arabidopsis sequencing project and contains some 24,000 genes. TIGR's annotation data can be viewed at TIGR's website.<< A little support from ASCO: >>New approaches help diagnose cancer By Maggie Fox, Health and Science Correspondent ORLANDO, Florida, May 19 (Reuters) - New approaches to cancer, using "gene chips" and targeted drugs, may add a little something to the very limited arsenal used against some of the more hopeless cases, doctors said on Sunday. While none of the findings are huge breakthroughs, they show that a step-by-step approach can gradually improve the outlook for cancer patients, organizers of the annual conference of the American Society of Clinical Oncology said. Dr. Robert Maki of Memorial Sloan-Kettering Cancer Center in New York and colleagues used a gene chip made by Affymetrix (NasdaqNM:AFFX - News) to try to identify different kinds of sarcoma -- a very rare cancer that is actually a group of fairly different diseases. Knowing precisely the type of cancer is important for treating it. Doctors often lump them into one designation called malignant fibrous histiocytomas, and only about half of patients with this diagnosis live for any length of time. Maki said the gene chip helped his team more precisely identify what disease was involved -- and helped them separate the MFH sarcomas into several distinct subtypes. New drugs or other treatments might be designed to help such patients. "This will help pathologists (who identify samples of cancerous tissue) and it will help us come up with therapeutic options," Maki told a news conference.<< snip Cheers, Tuck